JP2007507482A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507482A5
JP2007507482A5 JP2006530728A JP2006530728A JP2007507482A5 JP 2007507482 A5 JP2007507482 A5 JP 2007507482A5 JP 2006530728 A JP2006530728 A JP 2006530728A JP 2006530728 A JP2006530728 A JP 2006530728A JP 2007507482 A5 JP2007507482 A5 JP 2007507482A5
Authority
JP
Japan
Prior art keywords
maleate
powder
salt
pattern including
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530728A
Other languages
English (en)
Japanese (ja)
Other versions
JP4933259B2 (ja
JP2007507482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/003070 external-priority patent/WO2005033098A1/en
Publication of JP2007507482A publication Critical patent/JP2007507482A/ja
Publication of JP2007507482A5 publication Critical patent/JP2007507482A5/ja
Application granted granted Critical
Publication of JP4933259B2 publication Critical patent/JP4933259B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2006530728A 2003-10-02 2004-09-20 ピロール置換インドリノン化合物の塩および多形 Expired - Fee Related JP4933259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
US60/508,104 2003-10-02
PCT/IB2004/003070 WO2005033098A1 (en) 2003-10-02 2004-09-20 Salts and polymorphs of a pyrrole-substituted indolinone compound

Publications (3)

Publication Number Publication Date
JP2007507482A JP2007507482A (ja) 2007-03-29
JP2007507482A5 true JP2007507482A5 (enExample) 2007-11-08
JP4933259B2 JP4933259B2 (ja) 2012-05-16

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530728A Expired - Fee Related JP4933259B2 (ja) 2003-10-02 2004-09-20 ピロール置換インドリノン化合物の塩および多形

Country Status (25)

Country Link
US (1) US7247627B2 (enExample)
EP (1) EP1670785B1 (enExample)
JP (1) JP4933259B2 (enExample)
KR (2) KR20060058728A (enExample)
CN (1) CN100432072C (enExample)
AR (1) AR047762A1 (enExample)
AT (1) ATE473223T1 (enExample)
AU (1) AU2004277464B2 (enExample)
BR (1) BRPI0415022A (enExample)
CA (1) CA2540639C (enExample)
CY (1) CY1110771T1 (enExample)
DE (1) DE602004028028D1 (enExample)
DK (1) DK1670785T3 (enExample)
ES (1) ES2348623T3 (enExample)
IL (1) IL174414A (enExample)
MX (1) MXPA06003661A (enExample)
NO (1) NO20061246L (enExample)
NZ (1) NZ546001A (enExample)
PL (1) PL1670785T3 (enExample)
PT (1) PT1670785E (enExample)
RU (1) RU2319702C2 (enExample)
SI (1) SI1670785T1 (enExample)
TW (1) TW200524921A (enExample)
WO (1) WO2005033098A1 (enExample)
ZA (1) ZA200602691B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
KR101428833B1 (ko) * 2007-04-04 2014-08-08 오츠카 가가쿠 가부시키가이샤 티탄산칼륨, 그의 제조 방법, 마찰재 및 수지 조성물
KR101129088B1 (ko) * 2008-09-17 2012-03-23 노파르티스 아게 N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
RU2430361C1 (ru) * 2010-07-05 2011-09-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575936A3 (ru) * 1986-04-10 1990-06-30 Е.И.Дюпон Де Немур Энд Ко.(Фирма) Способ получени 3,3-дизамещенных индолин-2-ионов или их солей
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
JP2005528344A (ja) 2002-02-15 2005-09-22 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー インドリノン誘導体の製造法
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas

Similar Documents

Publication Publication Date Title
JP2011522816A5 (enExample)
JP2005518433A5 (enExample)
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
JP2010528026A5 (enExample)
JP2005524658A5 (enExample)
PL2046298T3 (pl) Farmaceutyczna postać dawkowania zawierająca farmaceutycznie dopuszczalną kompozycję solubilizującą
IL181304A (en) Use of dihydroprididone for the preparation of a drug for the treatment of spinal cord dysplasia
JP2009500443A5 (enExample)
JP2008539268A5 (enExample)
JP2008516004A5 (enExample)
JP2012516344A5 (enExample)
JP2014527042A5 (enExample)
JP2013522326A5 (enExample)
EP3276004A3 (en) Methods for treating chronic kidney disease
JP2012512158A5 (enExample)
JP2012505884A5 (enExample)
JP2014507412A5 (enExample)
JP2008513510A5 (enExample)
JP2008536853A5 (enExample)
RU2015119218A (ru) Комбинация
IL179777A (en) Dosage Forms Dosage Forms Dissipating Fast Dissolving Solid Form Dissolving Containing This Preparation
JP2004529117A5 (enExample)
RU2006110541A (ru) Соли и полиморфы пиррол-замещенного соединения индолинона
JP2013537901A5 (enExample)
RU2016116915A (ru) Комбинация